Therapeutic potential of compounds targeting SARS-CoV-2 helicase

Matthew T.J. Halma; Mark J.A. Wever; Sanne Abeln; Didier Roche; Gijs J.L. Wuite

doi:10.3389/fchem.2022.1062352

Therapeutic potential of compounds targeting SARS-CoV-2 helicase

Matthew T.J. Halma
, Mark J.A. Wever
, Sanne Abeln
, Didier Roche
, Gijs J.L. Wuite

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.

Original language	English
Pages (from-to)	1-12
Number of pages	12
Journal	Frontiers in Chemistry
Volume	10
DOIs	https://doi.org/10.3389/fchem.2022.1062352
Publication status	Published - 6 Dec 2022
Externally published	Yes

Bibliographical note

Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 859853. Publisher Copyright: Copyright © 2022 Halma, Wever, Abeln, Roche and Wuite.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
drug repurposing
helicase
natural products
nsp13
SARS-CoV-2
small-molecule inhibitors

Access to Document

10.3389/fchem.2022.1062352

Cite this

@article{3dbeb00a64394fdf8c3cf05d0b3884a3,

title = "Therapeutic potential of compounds targeting SARS-CoV-2 helicase",

abstract = "The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8\% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.",

keywords = "COVID-19, drug repurposing, helicase, natural products, nsp13, SARS-CoV-2, small-molecule inhibitors",

author = "Halma, \{Matthew T.J.\} and Wever, \{Mark J.A.\} and Sanne Abeln and Didier Roche and Wuite, \{Gijs J.L.\}",

note = "Funding Information: This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation program under the Marie Sk{\l}odowska-Curie grant agreement No 859853. Publisher Copyright: Copyright {\textcopyright} 2022 Halma, Wever, Abeln, Roche and Wuite.",

year = "2022",

month = dec,

day = "6",

doi = "10.3389/fchem.2022.1062352",

language = "English",

volume = "10",

pages = "1--12",

journal = "Frontiers in Chemistry",

issn = "2296-2646",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Therapeutic potential of compounds targeting SARS-CoV-2 helicase

AU - Halma, Matthew T.J.

AU - Wever, Mark J.A.

AU - Abeln, Sanne

AU - Roche, Didier

AU - Wuite, Gijs J.L.

N1 - Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 859853. Publisher Copyright: Copyright © 2022 Halma, Wever, Abeln, Roche and Wuite.

PY - 2022/12/6

Y1 - 2022/12/6

N2 - The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.

AB - The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.

KW - COVID-19

KW - drug repurposing

KW - helicase

KW - natural products

KW - nsp13

KW - SARS-CoV-2

KW - small-molecule inhibitors

U2 - 10.3389/fchem.2022.1062352

DO - 10.3389/fchem.2022.1062352

M3 - Article

SN - 2296-2646

VL - 10

SP - 1

EP - 12

JO - Frontiers in Chemistry

JF - Frontiers in Chemistry

ER -

Therapeutic potential of compounds targeting SARS-CoV-2 helicase

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this